Kim-Maren Stegmann

Kim-Maren Stegmann

Auto-generated profile, based on publicly available information

Kim-Maren Stegmann

Department of Molecular Oncology, Göttingen Center of Molecular Biosciences (GZMB), University Medical Center Göttingen, Justus-von-Liebig-Weg 11, 37077, Göttingen, Germany

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 August 2021 in The EMBO Journal
Verified
Journal Article
Open access
PDF file
TGThomas Güttler
Thomas Güttler
MAMetin Aksu
Metin Aksu
ADAntje Dickmanns
Antje Dickmanns
KSKim M. Stegmann
Kim M. Stegmann
KGKathrin Gregor
Kathrin Gregor
DGDirk Görlich
Dirk Görlich
EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.

1 September 2021 in Virus Research
Verified
Journal Article
Closed access
KSKim M. Stegmann
Kim M. Stegmann
ADAntje Dickmanns
Antje Dickmanns
SGSabrina Gerber
Sabrina Gerber
VNVella Nikolova
Vella Nikolova
LKLuisa Klemke
Luisa Klemke
MDMatthias Dobbelstein
Matthias Dobbelstein

29 July 2025 in Antiviral Research
Verified
Journal Article
Open access
DKDoha Al Krad
Doha Al Krad
KSKim M. Stegmann
Kim M. Stegmann
ADAntje Dickmanns
Antje Dickmanns
PKPriya Kumar
Priya Kumar
CBClaudia Blaurock
Claudia Blaurock
MDMatthias Dobbelstein
Matthias Dobbelstein
Nirmatrelvir, the active compound of the drug Paxlovid, inhibits the Main protease of SARS-CoV-2 (MPro, 3CLPro, NSP5). Its therapeutic application reduces but does not abolish the progression of COVID-19 in humans. Here we report a strong synergy of Nirmatrelvir with inhibitors of the ER chaperone GRP78 (HSPA5, BiP). Combining Nirmatrelvir with the GRP78-antagonizing drug candidate HA15 strongly inhibits the replication of SARS-CoV-2, to a far greater extent than either drug alone, as observed by diminished cytopathic effect, levels of detectable virus RNA, TCID50 titers, and reduced accumulation of the non-structural proteins, as well as Spike and N proteins. The original SARS-CoV-2 strain as well as an Omicron variant were similarly susceptible towards the drug combination. Other GRP78 inhibitors or siRNAs targeting GRP78 also fortified the antiviral effect of Nirmatrelvir. In a hamster model of COVID-19, the combination of Nirmatrelvir with HA15 alleviated pneumonia-induced pulmonary atelectasis more effectively than the single drugs. In conclusion, inhibition of the virus Main protease and cellular GRP78 cooperatively diminishes virus replication and may improve COVID-19 therapy.

28 June 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
KSKim M. Stegmann
Kim M. Stegmann
ADAntje Dickmanns
Antje Dickmanns
NHNatalie Heinen
Natalie Heinen
Uwe GroßUwe Groß
Uwe Groß
DGDirk Görlich
Dirk Görlich
MDMatthias Dobbelstein
Matthias Dobbelstein
Effective therapeutics to inhibit the replication of SARS-CoV-2 in infected individuals are still under development. The nucleoside analogue N4-hydroxycytidine (NHC), also known as EIDD-1931, interferes with SARS-CoV-2 replication in cell culture. It is the active metabolite of the prodrug Molnupiravir (MK-4482), which is currently being evaluated for the treatment of COVID-19 in advanced clinical studies. Meanwhile, inhibitors of dihydroorotate dehydrogenase (DHODH), by reducing the cellular synthesis of pyrimidines, counteract virus replication and are also being clinically evaluated for COVID-19 therapy. Here we show that the combination of NHC and DHODH inhibitors such as teriflunomide, IMU-838/vidofludimus, and BAY2402234, strongly synergizes to inhibit SARS-CoV-2 replication. While single drug treatment only mildly impaired virus replication, combination treatments reduced virus yields by at least two orders of magnitude. We determined this by RT-PCR, TCID 50 , immunoblot and immunofluorescence assays in Vero E6 and Calu-3 cells infected with wildtype and the Alpha and Beta variants of SARS-CoV-2. We propose that the lack of available pyrimidine nucleotides upon DHODH inhibition increases the incorporation of NHC in nascent viral RNA, thus precluding the correct synthesis of the viral genome in subsequent rounds of replication, thereby inhibiting the production of replication competent virus particles. This concept was further supported by the rescue of replicating virus after addition of pyrimidine nucleosides to the media. Based on our results, we suggest combining these drug candidates, which are currently both tested in clinical studies, to counteract the replication of SARS-CoV-2, the progression of COVID-19, and the transmission of the disease within the population. SIGNIFICANCE: The strong synergy displayed by DHODH inhibitors and the active compound of Molnupiravir might enable lower concentrations of each drug to antagonize virus replication, with less toxicity. Both Molnupiravir and DHODH inhibitors are currently being tested in advanced clinical trials or are FDA-approved for different purposes, raising the perspective of rapidly testing their combinatory efficacy in clinical studies. Molnupiravir is currently a promising candidate for treating early stages of COVID-19, under phase II/III clinical evaluation. However, like Remdesivir, it appears only moderately useful in treating severe COVID-19. Since the combination inhibits virus replication far more strongly, and since DHODH inhibitors may also suppress excessive immune responses, the combined clinical application bears the potential of alleviating the disease burden even at later stages.

13 May 2024 in Nucleosides, Nucleotides & Nucleic Acids
Verified
Journal Article
Closed access
KUKrzysztof Urbanowicz
Krzysztof Urbanowicz
MOMikolaj Opielka
Mikolaj Opielka
KSKim M. Stegmann
Kim M. Stegmann
ADAntje Dickmanns
Antje Dickmanns
MDMatthias Dobbelstein
Matthias Dobbelstein
RSRyszard T. Smolenski
Ryszard T. Smolenski
Molnupiravir, an orally administered prodrug of β-d-N4-hydroxycytidine (NHC), is incorporated into newly synthesized RNA by viral RNA-dependent RNA polymerase (RdRp). It is used for treatment of SARS-CoV-2 infections. Incorporation of NHC triphosphate into viral RNA inhibits replication of the virus, at least in part by introducing deleterious mutations. However, there is limited information on NHC incorporation into host RNA and reports on the risk of mutagenicity that molnupiravir/NHC pose to the host are conflicting. We used two liquid chromatography-mass spectrometry (LC-MS) methods to evaluate the incorporation of NHC into RNA and DNA of host Vero E6 cells in a SARS-CoV-2 infection model. To test this, host and viral RNA were degraded to their ribonucleosides, while host DNA was degraded to deoxyribonucleosides. Subsequently, nucleic acid constituents were analyzed by LC-MS, which offers specific, direct, and quantitative determination of incorporation. Our findings revealed concentration dependent NHC incorporation into host cell RNA in both infected and uninfected cell cultures, reaching a maximum of 1 in 7,093 bases. Analysis of host DNA revealed no presence of deoxy-N4-hydroxycytidine down to a detection limit of 1 in 133,000 bases. Our findings therefore suggest minimal to no NHC incorporation into host DNA, indicating a low probability of significant host cell mutagenicity associated with its use.

19 April 2022 in bioRxiv
Verified
Preprint
Open access
PDF file
LFLisa-Marie Funk
Lisa-Marie Funk
GPGereon Poschmann
Gereon Poschmann
ACAshwin Chari
Ashwin Chari
FPFabian Rabe von Pappenheim
Fabian Rabe von Pappenheim
KSKim-Maren Stegmann
Kim-Maren Stegmann
KTKai Tittmann
Kai Tittmann
A bstract: Besides vaccines, the development of antiviral drugs targeting SARS-CoV-2 is critical for stopping the current COVID-19 pandemic and preventing future outbreaks. The SARS-CoV-2 main protease (M pro ), a cysteine protease with essential functions in viral replication, has been validated as an effective drug target. Here, we show that M pro is subject to redox regulation and reversibly switches between the enzymatically active dimer and the functionally dormant monomer through redox modifications of cysteine residues. These include sulfenylation, disulfide formation between the catalytic cysteine and a proximal cysteine, and generation of an allosteric lysine-cysteine SONOS bridge that is required for structural stability under oxidative stress conditions, such as those exerted by the innate immune system. We identify homo- and heterobifunctional reagents that mimic the redox switching and possess antiviral activity. The discovered redox switches are conserved in main proteases from other coronaviruses, e.g. MERS and SARS-CoV, indicating their potential as common druggable sites.